International Journal of Research in Pharmacy and Pharmaceutical Sciences
ISSN: 2455-698X; Impact Factor: RJIF 5.22
Received: 13-11-2020; Accepted: 26-11-2020; Published: 16-12-2020
www.pharmacyjournal.in
Volume 5; Issue 6; 2020; Page No. 66-71

Disease profile of rheumatoid arthritis and it's management

Anandkumar S*, Nivashini T, Pavithra S, Poovitha T
Department of Pharmacy Practice, Swamy Vivekanandha College of Pharmacy, Tiruchengode, Namakkal, Tamil Nadu, India

Abstract
Rheumatoid joint inflammation (RA) is an immune system, provocative illness that causes torment, growing, solidness, and loss of capacity in different joints (most normally in the hands, wrists, and knees). The individual joint's coating gets aroused, prompting tissue harm, just as constant torment, precariousness, and deformity. There is commonly a respective/balanced example of sickness movement (e.g., two hands or the two knees are affected). Rheumatoid arthritis can likewise influence extra-articular locales, including the eyes, mouth, lungs, and heart. Rheumatoid joint pain is an ongoing infection influencing up to 1% of populaces in created nations. Certain hereditary and natural variables seem to advance the improvement of rheumatoid arthritis, however patients can give heterogeneous signs and side effects. The objectives of any treatment for rheumatoid arthritis are the decrease of irritation and reduction of infection. In momentum practice, there are a biological and manufactured Disease Modified Anti-Rheumatic Drugs that can decrease infection seriousness. The rules give direct frameworks toward illness characterization, stepwise calculations for treatment, and proposals for development and observing dependent on reaction and Co-morbidities.

Keywords: rheumatoid arthritis, management, drugs

Introduction
Rheumatoid arthritis is defined a systemic inflammatory disease which is characterized by persistent synovitis and production of auto-anti bodies against various factors, which includes rheumatoid factor and cyclic citrullinated peptide. Rheumatoid arthritis mostly affects the synovial lining of joints, although it targets the lungs, heart, blood vessels and including the other organ systems [1]. Rheumatoid arthritis results in substantial disability, loss of productivity, and increased mortality. In early disease function irreversible damage of joint and inflammatory changes are seen. In established Rheumatoid arthritis inflammation, pain, stiffness and fatigue are present [2].

Epidemiology
Epidemiology is the study of disease distribution and its determinants in human population. Incidence study is defined as study about all arising new cases in a defined period of time at specified population. Epidemiologic studies of risk factors fall into three major categories.1.Prospective cohort studies. 2. Retrospective cohort studies. 3. case control studies[3].
In, total adult population above 0. 5– 1. 0% of people are affected by Rheumatoid arthritis. This brings a heavy burden on healthcare systems [3]. Pathophysiology of rheumatoid arthritis is not correctly registered. Infective agents are indirect in this case of disease. Causative agents are identified same in some arthritis, such as reactive arthritis or lime disease. 60% risk of Rheumatoid arthritis is accounted by genetic factor. Female sex, smoking and people with shared epitome are included as major risk factor [4].

Pathogenesis
There are two significant subtypes of Rheumatoid Arthritis as per the presence or nonappearance of anti citrullinated protein antibodies (ACPAs). Citrullination is catalyzed by the calcium-subordinate protein Peptidyl- Arginine-Deiminase (PAD), changing an emphatically charged arginine to a polar however, unbiased citrulline as the consequence of a post-translational adjustment [5]. Anti Citrullinated Protein Antibodies can be recognized in around 67% of Rheumatoid arthritis patients and fill in as a valuable symptomatic reference for patients with ahead of schedule, undifferentiated joint inflammation and give a sign of likely illness movement through to rheumatoid arthritis [6]. The Anti Citrullinated Protein Antibodies -positive subset of rheumatoid arthritis has a more forceful clinical aggregate contrasted with Anti Citrullinated Protein Antibodies -negative subset of RA.10 It is accounted for that ACPA-negative Rheumatoid Arthritis has distinctive hereditary affiliation patterns11 and differential reactions of resistant cells to citrullinated antigens12 from those of Anti Citrullinated Protein Antibodies -positive subset. The stages involved in pathogenesis are 1) Triggering stage 2) Maturation stage3) Targeting stage 4) Fulminant stage.

Etiology
The specific reason for rheumatoid arthritis is as yet unclear, yet qualities, ecological components, and hormones might be associated with its immune system improvement and progression [7].Certain danger factors seem to build the danger of rheumatoid arthritis, including more
seasoned age, sex (higher rate in ladies); Hereditary qualities such as human leukocyte antigen [HLA] class II genotypes, smoking, early life introductions if mother smoked, youngster has more serious danger of rheumatoid arthritis and heftiness (higher danger with expanding body weight [8, 9]. Patients who are seropositive for anticitrullinated protein antibodies (ACPAs) or rheumatoid elements (RFs) additionally have an expanded danger of rheumatoid arthritis [10].

Clinical Manifestations
The increase in susceptibility to develop clinical manifestations of rheumatoid arthritis is a combination of environmental and genetic factor [11].

The Hand
Tender swelling on palpitation, several deformities, Boutonniere deformity, Swan neck deformity, dislocation of finger joints and tendons are associated with deformities, Small discrete, pocketed erosions near the capsular insertion.

The Knee
Muscle atrophy, Flexion contractures, Valgus instability, Large Bakers cysts, Inability to walk, Thrombophlebitis-like syndrome by popliteal cyst rupture.

The Hip
Osteopenia, Concentric articular cartilage narrowing, Hip pain, Severe disability, Hip abduction.

Bursal Involvement
The major cause of pain and functional impairment is bursitis. Early Rheumatoid arthritis shows olecra non bursitis commonly.

Constitutional Manifestations
Fatigue, Fever, Weight loss, Malaise

Variable Manifestations of Extra Articular Involvement
Rheumatoid nodules, Vasculitis, Hematologic abnormalities, Feltys syndrome [12]

Pathophysiology
The immune system and rheumatoid arthritis pathophysiology

In Rheumatoid arthritis, the synovial tissue is accumulated with naive and memory B cells, in which there B cells and high migratory capacity are cloned together and gets a continuous activation. Peripheral B-cells from Rheumatoid arthritis patients have a key molecule expression with high CD86 and low Fibroblast-like synoviocytes levels. ZAP-70 is an efficient molecule in T cell receptor signaling pathway includes the requirement of downstream effector molecules. T cell development and impaired response to TCR stimulation, distributed positive and negative thymic selection and reduced number of regulatory T cells are resulting from reduced mutation of two key scaffolding residues. Immune tolerance is regulated by regulatory T-cells. Anti-inflammatory therapy affects the complement cascade and it also activated by the macroparticles [13].

The role of auto antibodies in the pathophysiology of Rheumatoid Arthritis
The antibodies that are associated with both genetic and environmental risk factors such as rheumatoid factors, anti-citrullinated protein antibodies, anti carbomylated protein antibodies that can be sub divided into sero positive and negative. At recent Anti Citrullinated Protein Antibodies plays a vital role in inflammation. Thus Anti Citrullinated Protein Antibodies could bind to the antigens in the synovial fluid which increases local inflammation [14].
Citrullination and carbomylation in the pathophysiology of Rheumatoid Arthritis
Citrullination and carbomylation are responsible for the generation of immune response in auto immune disease Rheumatoid Arthritis. Since the process was still largely unknown but it has strong indication in modifying the proteins lung and gums that are induced by the environmental factors. In case of Rheumatoid Arthritis, many proteins are citrulllinated in the inflamed joints [15].

Diagnosis
The finding of Rheumatoid Arthritis depends on a high file of doubt dependent on a careful patient history and actual assessment.
In 2010, the American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) set forth the most current measures for the conclusion of Rheumatoid Arthritis [16]. The measures are (1) the number and site of included joints, (2) serologic anomalies (presence of rheumatoid factor or against citrullinated peptide/protein immunizer), (3) rises of incendiary markers (erythrocyte sedimentation rate as well as C-receptive protein [CRP]), and (4) the length of side effects [17].
These tests incorporate rheumatoid factor (RF), antibodies to cyclic citrullinated peptides, incendiary markers, for example, the erythrocyte sedimentation rate (ESR) and CRP, and fundamental lab work, for example, complete blood check and complete metabolic board [18].
Ultrasonography, particularly with Doppler [19]. Computed tomography imaging can be helpful for showing hard pathology. Magnetic Resonance Imaging has the additional capacity to envision synovial or delicate tissue association and cartilaginous deformities [20].

Pharmacological treatment
First line management
Non steroidal anti inflammatory drugs
Relieving pain and decreasing inflammation is a goal for first line management. Fast acting Non Steroidal Anti Inflammatory Drugs are Acetyl salicylate, Naproxen, Ibuprofen, etodolac. In high doses aspirin act as an effective anti inflammatory for Rheumatoid Arthritis because it inhibits the prostaglandins. It is prescribed for joint pain in rheumatoid arthritis. To prevent the synthesis of prostaglandins, prostacyclin and thrombaxane it inhibits the cyclooxygenase enzyme. When it taken with food, antacid, proton pump inhibitor, misoprostol it decreases the symptoms.

Side Effects
Common side effects are nausea, abdominal pain, ulcer, gastro intestinal bleeding.
At high dose tinnitus, hearing loss, gastric intolerance occurs [21].

Corticosteroid
Corticosteroid are more effective anti inflammatory medication than Non Steroidal Anti Inflammatory Drugs, but it has high side effects. So it is given only in low dose, when exacerbation and flares occurs. It reduces the inflammation by stopping the phospholipids and lowering the actions of eosinophils.

Side Effects
Bone thinning, weight gain, diabetes, immunosuppression.

Side effects get lowered by tapering the doses according to the patient's condition [21]. Do not discontinue oral or injected corticosteroids abruptly. It can lead to suppression of the hypothalamic pituitary-adrenal axis (HPA) or flares of rheumatoid arthritis [22].

Opioid Analgesics

In rheumatoid arthritis, pain is treated with weak opioids like codeine, dextro-propoxyphene and tramadol. These drugs are acts as a vital role. So it is used in short term management. They suggest that different analgesics are viewed as first [23].

Second line management

Disease modified anti rheumatic drugs

The general objective of second line treatment is to advance abatement by easing back or halting the movement of joint demolition and distortion. Prescriptions are viewed as moderate acting since they take from weeks to months to be successful. Disease modifying Anti-rheumatic Drugs additionally decreases the danger of creating lymphoma that can be related with rheumatoid arthritis [24].

Methotrexate is the underlying second line drug (additionally considered as an anchor drug). It is a simple to folic corrosive that seriously restrains the authoritative of di-hydro folic corrosive (FH_2) to the chemical that is liable for changing over FH_2 to folinic corrosive (FH_4). Methotrexate is an immunosuppressive medication that requires customary blood test because of its results of liver issues, cirrhosis and bone marrow crumbling [25].

Hydroxychloroquine is an anti malarial sedate and can be utilized long term in the treatment of rheumatoid joint pain. This medication diminishes the emission of monocyte-determined proinflammatory cytokines [26].

Sulfasalazine (Azulfidine) is a Disease Modified Anti Rheumatic Drug commonly utilized in the treatment of peevish gut illness. Joined with calming meds, this Disease Modified Anti Rheumatic Drug can be utilized to treat rheumatoid arthritis. The system of activity of this medication in the treatment of Rheumatoid Arthritis has not been distinguished. It is believed that sulfa-pyridine, a decreased type of the drug after organization, may diminish discharges of interleukin (IL) - 8 and monocyte chemo-attractant protein (MCP). This medication has results of Gastro Intestinal and focal sensory system indications just as rash. It is normally all around endured among patients, yet should be evaded in patients with sulfa sensitivities since it contains sulfa and salicylate mixes [27].

Gold salts, for example, aurothioglucose (Solganal), auranofin (Ridaura), gold sodium thiomalate (Myochrysine), and D-penicillamine (Depen and Cuprimine) have been utilized regularly in the treatment of Rheumatoid Arthritis. These Disease Modified Anti Rheumatic Drugs require regular blood and pee tests because of harm deep down marrow and kidneys. They have not been utilized as of late because of the more compelling medicines, especially Methotrexate [28]. Other immunosuppressive drugs like azathioprine (Imuran), cyclophsphamide (Cytoxan), chlorambucil (Leukeran), and cyclosporine (Sandimmune) can be utilized yet are normally held for patients with forceful Rheumatoid Arthritis or intricacies of the infection [29].

Newer Medications

Leflunomide is an oral drug that is changed over to malononitrilamide, which represses the union of ribonucleotide uridine monophosphate pyrimidine. It calms indications and retards the movement of Rheumatoid Arthritis. It is prescribed to be utilized in blend with MTX however can establish a monotherapy if patients don't react to Methotrexate [30]. Results incorporate hypertension, Gastro Intestinal steamed, liver harm, leukopenia, interstitial lung sickness, neuropathy, rash, and bone marrow harm [31].

Biologics, otherwise called Natural Disease Modified Anti Rheumatic Drugs, are quickly compelling in impeding the movement of the joint harm brought about by Rheumatoid Arthritis. They are viewed as a more "immediate, characterized and focused on" strategy for treatment [32]. In any case, biologics represent the issue of genuine results, for example, expanded danger of diseases. Other basic results incorporate neurologic sicknesses like various sclerosis and lymphoma [33].

Tumor Necrosis factor (TNF) is a courier protein that advances aggravation in joints. Biologic drugs, for example, etanercept (Enbrel), infliximab (Remicade), adalimumab (Humira), golimumab (Simponi), and certolizumab pegol (Cimzia) are all TNF inhibitors that forestall the enrollment of the phones that cause aggravation, bringing fast indication alleviation. They are suggested if other second-line meds are not successful [34]. Sadly, these prescriptions will in general be pricey and their part in treating patients at different phases of Rheumatoid Arthritis and with different instruments of activity involves nonstop examination [35]. They are regularly utilized in mix with other Disease Modified Anti Rheumatic Drugs, particularly Methotrexate. TNF inhibitors are contraindicated in patients with congestive cardiovascular breakdown of demyelinating infections. Each biologic prescription has an alternate method of organization [36].

Anakinra (Kineret) is a medication that is infused subcutaneously day by day. It works by official to Interleukin-1, a synthetic courier of irritation. It very well may be utilized in mix with other Disease Modified Anti Rheumatic Drugs or as a monotherapy, however due its low reaction rate contrasted with other biologics, it isn't utilized as regularly [37].

Rituximab (Rituxan) is helpful in Rheumatoid Arthritis since it exhausts the B cells answerable for aggravation and the creation of unusual antibodies. Regularly utilized in the treatment of lymphoma, this medication can be utilized in instances of Rheumatoid Arthritis where TNF inhibitors have fizzled. Also, rituximab has indicated benefits in treating the inconveniences of Rheumatoid Arthritis, for example, vasculitis and cryoglobulinemia. It is regulated as an intravenous implantation in 2 dosages, fourteen days separated, like clockwork [38].

Abatacept (Orencia) is a biologic prescription that works by hindering T cell actuation. This is given as an intravenous imbuement once every month or subcutaneously once per week. It is utilized in patients who have not been viably treated with customary Disease Modified Anti Rheumatic Drugs [39].

Tocilizumab (Actemra) is a biologic that works by hindering IL-6, a synthetic courier of irritation. It is managed by means of intravenous implantation given month to month or through week after week subcutaneous infusions. It is likewise utilized for patients who have not

been viably treated with conventional Disease Modified Anti Rheumatic Drugs [40].

Finally, tofacitinib (Xeljanz) has an alternate instrument of activity and works by obstructing Janus kinases inside cells, which are chemicals of aggravation. Therefore, it is known as a JAK inhibitor. This drug is utilized for patients who have not been viably treated with Methotrxate. Tofacitinib is taken orally twice day by day, alone or in blend with Methotrexate. It not be utilized in blend with customary biologic prescriptions or other intense immunosuppressants [41].

Surgery

Joint a medical procedure in patients with Rheumatoid Arthritis arrived at a top during the 1990s. Be that as it may, a recent report demonstrated diminished paces of joint a medical procedure in RA patients 40–59 years old. Conversely, patients more established than 60 years had expanded paces of a medical procedure [42].

A tenosynovectomy includes the extraction of excited ligament sheaths or fixing an ongoing ligament burst, most ordinarily in the hand [43].

Radiosynovectomy is an option in contrast to careful synovectomy; it includes intra-particular infusion of little radioactive particles, is savvy, and can treat different joints at the same time [44].

Another careful choice is osteotomy. In this methodology, weight-bearing bones are realigned to address valgus or varus distortions, most normally in the knee [45]. Metatarsal-head extraction arthroplasty is done to mitigate extreme forefoot torment. Ultimately, an absolute joint substitution includes eliminating the harmed joint and supplanting it with a metallic, plastic, or clay prosthesis. This is most usually done in the shoulder, elbow, wrist, hip, knee, and lower leg [46].

Non Pharmacological Management

The non pharmacological therapy mainly includes physical and rehabilitation interventions. It includes exercise, physical modalities, orthoses, dietary interventions, assistive devices and balneo therapy, Therapeutic patient education.

Therapeutic Patient Education

It aims to educate the patient about their disease, treatment, movements to prevent joint, lifestyle changes.

Exercise Therapy

Exercise and physical activity is essential in non pharmacological therapy. It increases the muscle strength aerobic capacity, improves joint range of movement, balance and flexibility. It is effective in cardiovascular fitness and muscle strength.

Physical Modalities

The patient with inflammatory arthritis are advised for rehabilitation practice like heat, cold and other physical modalities which aims in relieving pain, stiffness, increase flexibility and restoring function, It include Thermotherapy, Electrotherapy, Low level laser therapy, whole body vibration.

Orthoses

It is an externally applied device used to modify the structural and functional characteristic of neuro-muscular and skeletal system. It includes Wrist hand orthoses, Foot orthoses and footwear

Dietary Interventions

Its purpose include decreases in inflammatory process, increase in anti-oxidants modifying intestinal flora, elimination of offending foods.

Balneotherapy

It includes mineral bath, mud packs, carbondioxide baths. The overall evidence was insufficient to prove that balneo therapy is effective [47].

Various dietary plans are being projected; some are 7-10 days fasting, vegan or mediterranean diets.

7 Days Fasting Followed By Vegan Diet

The diet includes limited amount of vitamin, minerals, and carbohydrates. The diet contains vegetables broth, herbal teas, parsely, garlic, decoction of potatoes, carrot and celery juice followed by 1 year of vegan diet. The diet shows a remarkable decrease in swelling and tender joints, pain, erythrocyte sedimentation rate and C-reactive protein.

Mediterranean Diet

The diet is rich in oleic acid, omega 3 fatty acid, unrefined carbohydrates and physicals to chemicals. The diet involves olive oil, cereals, fruits, vegetables, fish, legumes, less red meat and small amount of red wine. It shows reduced inflammation, vitality and physical function.

Dietary Fibres and Whole Grains

Recommendation of dietary intake with limits of 14g per 1000 kcal 25 and 38g for adult for both sex, has health benefits.

Fruits

The fresh fruits are rich in bioactive components and phytochemicals that are essential in reducing oxidative stress and inflammation. Other dietary includes, Spices, Essential Fatty Acid, Synbiotics-Probiotics, Prebiotics and Herbs [48].

Conclusion

Rheumatoid Arthritis, a typical immune system infection, is related to irritation and expanding of the synovium of the joint and, whenever left untreated, frequently results in destruction of both the hard and cartilaginous components of the joint and resultant inability. An assortment of comorbidities related to foundational aggravation adds to the expanded mortality found in patients with Rheumatoid Arthritis thought about with everybody. Despite the fact that the pathophysiology of Rheumatoid Arthritis isn't totally perceived, the cycle by and large includes dys-regulated aggravation, with hostile to- gen introduction, T-cell actuation, and autoantibody creation all filling in as middle people in the incendiary measure. Determination of Rheumatoid Arthritis depends on the patient his-conservative and actual assessment showing synovitis in various joints. Records of sickness movement have been developed to direct treat-to-target ways to deal with pharmacological intercession.

References

1. Angelo G, Kenneth G, Jeffrey RC *et al*. Treatment of

rheumatoid arthritis; American Journal of pharmacy and health. 2006; 63(1):2451-2456.
2. Peter T, Theodorev P, David Y *et al*. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis; The New England Journal of Medicine, 1995, 333(20).
3. Sherine E Gabriel. The epidemiology of rheumatoid arthritis; rheumatic disease clinics of North America, 2001, 27(2).
4. Patrick JW, Venables. Infection and rheumatoid arthritis; current science. 1989; 1:15-20.
5. Nishimura K. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis; Annals of Internal Medicine. 2007; 146:797-808.
6. Bizzaro, Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis; Arthritis Research and Therapy, 2013, 15(16).
7. Smolen JS, Aletaha D. Rheumatoid arthritis; Lancet. 2016; 388(10055):2023-2038.
8. Smolen JS, Aletaha D. Rheumatoid arthritis; Nature Reviews Disease Primers. 2018; 4:18001.
9. Kourilovitch M, Galarza-maldonadoc, Ortiz-prad. Diagnosis and classification of rheumatoid arthritis; Journal of Autoimmunity. 2014; 49:26-30.
10. Walter Grassi, Rossella De Angelis, Gianni lamanna *et al*. The clinical features of rheumatoid arthritis; European Journal of Radiology. 1998; 21:18-24.
11. Faye AH Cooles, John D. Isaacs Pathophysiology of rheumatoid arthritis; Current opinion in rheumatology. 2011; 23:233-240.
12. VFAM Derksen, TWJ Huizinga D. The role of auto antibodies in the pathophysiology of rheumatoid arthritis, seminar in Immunopathology-Elseiver. 2017; 39(4):437-446.
13. Ger JM. Prujin citrullination and carbamylation in the pathophysioloy of rheumatoid arthritis; Frontiers immunology journal. 2015; 6(192):1-5.
14. Aletaha D, Neogi T, Silman A *et al*. rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative; Arthritis and Rheumatism. 2010; 62(9):2569-2581.
15. Nishimura K, Sugiyama D, Kogata Y *et al*. Meta-analysis: diagnostic accuracy ofanti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoidarthritis; Annals of Internal Medicine. 2007; 146:797.
16. Aletaha D, Neogi T, Silman A *et al*. rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis and Rheumatism. 2010; 62(9):2569–81.
17. Arnett F, Edworthy S, Bloch D *et al*. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis; Arthritis and Rheumatism. 1988; 31(3):315-24.
18. Nishimura K, Sugiyama D, Kogata Y *et al*. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis; Annals of Internal Medicine, 2007, 146:797.
19. Wakefield RJ, Gibbon WW, Conaghan PG *et al*. The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography; Arthritis and Rheumatism. 2000; 43:2762-70.
20. McQueen FM, Stewart N, Crabbe J *et al*. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset; Annals of Rheumatic Disease. 1998; 57:350.
21. Smolen J, Breedveld F, Burmester G *et al*. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force; Annals of Rheumatic Disease. 2015; 75(1):3-15.
22. McQueen FM, Stewart N, Crabbe J *et al*. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset; Annals of Rheumatic Disease. 1998; 57:350.
23. Ong CK, Lirk P, Tan CH *et al*. An evidence-based update on non-steroidal anti-inflammatory drugs; Clinical Medical Research. 2007; 5(1):19-34.
24. Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-Gracia JM *et al*. update of the EULAR recommendations for the management of early arthritis. Annals of Rheumatic Disease 2017. 2016; 76(6):948-959.
25. Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R *et al*. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy; Allergy Asthma and Clinical Immunology. 2013; 9(1):30.
26. Richards BL, Whittle SL, van der Heijde DM *et al*. The efficacy and safety of antidepressants in inflammatory arthritis: a Cochrane systematic review; Journal of Rheumatology Supplement. 2012; 90:21-27.
27. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti-rheumatic drugs; Annals of Rheumatic Disease. 2010; 69(6):964- 75.
28. Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis; Bulletin NYU Hospital for Joint Disease. 2007; 65(3):168-173.
29. Silva JC, Mariz HA, Rocha LF Jr *et al.*, Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients; Clinics (São Paulo). 2013; 68(6):766-771.
30. Volin MV, Harlow LA, Woods JM, Campbell PL. Treatment with sulfasalazine or sulfapyridine, but not 5-aminosalicyclic acid, inhibits basic fibroblast growth factor-induced endothelial cell chemotaxis; Rheumatoid Arthritis. 1999; 42(9):1927-1935.
31. Sailaja AK. An overall review on rheumatoid arthritis; International Journal of Current Pharmaceutical Research. 2014; 4:1138-1143.
32. Kumar P, Banik S. Pharmacotherapy options in rheumatoid arthritis; Clinical Medicine Insights Arthritis and Musculoskeletal Disorders. 2013; 6:35-43.
33. Fox RI, Herrmann ML, Frangou CG *et al*. How does leflunomide modulate the immune response in rheumatoid arthritis? Bio Drugs. 1999; 12(4):301-315.
34. Gibofsky A. Combination therapy for rheumatoid arthritis in the era of biological; HSS Journal. 2006;

2(1):30-41.
35. Rein P, Mueller RB. Treatment with Biologicals in Rheumatoid Arthritis: an Overview; Rheumatology and Therapy. 2017; 4(2):247-261.
36. Gay RD, Clarke AW, Elgundi Z, Domagala T, Le NB. Anti-TNFα domain antibody construct CEP-37247: full antibody functionality at half the size. MAbs. 2010; 2(6):625-38.
37. Lis K, Kuzawinska O, Bałkowiec-Iskra E. Tumor necrosis factor inhibitors - state of knowledge. Archives of Medical Science. 2014; 10(6):1175-1185.
38. Perpétuo IP, Caetano-Lopes J, Rodrigues AM *et al*. Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Rheumatoid Arthritis; Bio Med Research International, 2017, 2690402.
39. Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care; Clinical Therapeutic journal. 2011; 33(6):679-707.
40. Mok CC. Rituximab for the treatment of rheumatoid arthritis: an update; Drug Design Development and Therapy. 2013; 8:87-100.
41. Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update; BMC Med. 2013; 11(1):88.
42. Gomez-Gomez GJ, Masedo A, Yela C *et al.*, Current stage ininflammatory bowel disease: what is next? World J Gastroenterology. 2015; 21(40):11282-303.
43. Louie GH, Ward MM. Changes in the rates of joint surgery among patients with rheumatoid arthritis in California, 1983-2007. Annals of the Rheumatic Diseases. 2010; 69(5):868-71.
44. Knut L. Radiosynovectomy in the therapeutic management of arthritis. World Journal of Nuclear Medicine. 2015; 14(1):10-5
45. Puddu G, Cipolla M, Cerullo G, Franco V. Which osteotomy for a valgus knee? International Orthopaedics. 2010; 34(2):239-47.
46. Rheumatic surgery-overview/Surgical treatment-general opinions. Acta Orthop Scand. 2000; 72:8-14.
47. Ayse, Kucukdeveci. Non pharmacological treatment in established rheumatoid arthritis Elsevier. 2020; 33(5):1-15
48. Shweta Khanna, Kumar Sagar Jaiswal, Bhavana Gupta. Managing rheumatoid arthritis with dietary interventions; Frontiers in nutrition journal. 2017; 4(52):1-16.